Nkarta (NKTX) Free Cash Flow (2019 - 2026)
Nkarta's quarterly Free Cash Flow came in at -$28.6 million in Q1 2026, up 5.04% year-on-year from -$27.2 million in Q1 2025, and down 28.84% quarter-over-quarter from -$22.2 million in Q4 2025.
Nkarta has reported Free Cash Flow for 8 years, with the latest figure at -$28.6 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 5.04% year-over-year to -$28.6 million; the trailing twelve-month figure through Mar 2026 stood at -$88.4 million (up 16.26% YoY), and the FY2025 full-year result was -$89.9 million, up 13.64% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$28.6 million, down from -$22.2 million in the prior quarter.
- The five-year high for Free Cash Flow was -$18.7 million in Q3 2025, with the low at -$42.4 million in Q4 2022.
- Average Free Cash Flow over 5 years is -$25.9 million, with a median of -$25.6 million recorded in 2023.
- Year-over-year, Free Cash Flow plunged 127.0% in 2022 and advanced 28.81% in 2023.
- Tracing NKTX's Free Cash Flow over 5 years: stood at -$42.4 million in 2022, then increased by 28.81% to -$30.2 million in 2023, then gained by 14.28% to -$25.9 million in 2024, then gained by 14.11% to -$22.2 million in 2025, then retreated by 28.84% to -$28.6 million in 2026.
- The last three Free Cash Flow figures came in at -$28.6 million (Q1 2026), -$22.2 million (Q4 2025), and -$18.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | -28.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.61 Mn |
| Mar 31, 2026 | -28.61 Mn |
| Dec 31, 2025 | -22.21 Mn |
| Dec 31, 2025 | -22.21 Mn |
| Sep 30, 2025 | -18.68 Mn |
| Sep 30, 2025 | -18.68 Mn |
| Jun 30, 2025 | -18.89 Mn |
| Jun 30, 2025 | -18.89 Mn |
| Mar 31, 2025 | -30.13 Mn |
| Mar 31, 2025 | -30.13 Mn |
| Dec 31, 2024 | -25.85 Mn |
| Dec 31, 2024 | -25.85 Mn |
| Sep 30, 2024 | -25.32 Mn |
| Sep 30, 2024 | -25.32 Mn |
| Jun 30, 2024 | -24.25 Mn |
| Jun 30, 2024 | -24.25 Mn |
| Mar 31, 2024 | -28.68 Mn |
| Mar 31, 2024 | -28.68 Mn |
| Dec 31, 2023 | -30.16 Mn |
| Dec 31, 2023 | -30.16 Mn |
| Sep 30, 2023 | -26.46 Mn |
| Sep 30, 2023 | -26.46 Mn |
| Jun 30, 2023 | -32.10 Mn |
| Jun 30, 2023 | -32.10 Mn |
| Mar 31, 2023 | -25.58 Mn |
| Mar 31, 2023 | -25.58 Mn |
| Dec 31, 2022 | -42.37 Mn |
| Dec 31, 2022 | -42.37 Mn |
| Sep 30, 2022 | -22.47 Mn |
| Sep 30, 2022 | -22.47 Mn |
| Jun 30, 2022 | -19.24 Mn |
| Jun 30, 2022 | -19.24 Mn |
| Mar 31, 2022 | -20.03 Mn |
| Mar 31, 2022 | -20.03 Mn |
| Dec 31, 2021 | -18.67 Mn |
| Dec 31, 2021 | -18.67 Mn |
| Sep 30, 2021 | -19.78 Mn |
| Sep 30, 2021 | -19.78 Mn |
| Jun 30, 2021 | -18.83 Mn |
| Jun 30, 2021 | -18.83 Mn |
| Mar 31, 2021 | -15.68 Mn |
| Mar 31, 2021 | -15.68 Mn |
| Dec 31, 2020 | -13.92 Mn |
| Dec 31, 2020 | -13.92 Mn |
| Sep 30, 2020 | -13.75 Mn |
| Sep 30, 2020 | -13.75 Mn |
| Jun 30, 2020 | -12.73 Mn |
| Jun 30, 2020 | -12.73 Mn |
| Mar 31, 2020 | -10.61 Mn |
| Mar 31, 2020 | -10.61 Mn |
| Dec 31, 2019 | -7.26 Mn |
| Dec 31, 2019 | -7.26 Mn |
| Sep 30, 2019 | -5.25 Mn |
| Sep 30, 2019 | -5.25 Mn |